Tα1-RGDR

For the immune support applications most community users are seeking (immune optimization, immune aging mitigation, anti-viral support), unmodified Thymosin Alpha-1 (Zadaxin; thymalfasin) has a far more developed evidence base: Phase 3 clinical trials for hepatitis B and C; approved in 35+ countries; cancer immunoadjuvant data; COVID-19 clinical programs; extensive safety data. Tα1-RGDR has two mouse tumor model papers. The RGDR modification's tumor-targeting mechanism is not obviously relevant when there is no tumor to target. For community immune support applications, the companion chapter (pbta1v4) covering full TA1 provides the appropriate evidence context.

The RGDR targeting mechanism is specifically relevant for users with confirmed solid tumors expressing integrin αvβ3 (common in lung, melanoma, pancreatic, ovarian, and other solid cancers). In this context, Tα1-RGDR's tumor targeting could theoretically concentrate TA1's immune activation at the tumor site. This is the research rationale. No clinical validation exists for this theoretical benefit. Anyone considering Tα1-RGDR in an oncological context should involve their oncologist — the compound could theoretically interact with checkpoint inhibitors, chemotherapy, or other immunomodulatory treatments.

Thymosin Alpha-1 (Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu; 28 AA; MW ~3108 Da): the N-terminal acetylation (Ac-Ser) is required for biological activity. TA1 signals through Toll-like receptor 9 (TLR9) and STAT1/STAT3 signaling pathways; it promotes T-cell maturation and differentiation from thymic precursors; it enhances dendritic cell antigen presentation capacity; it upregulates CD4+ and CD8+ T cell populations; it increases NK cell activity; it modulates the inflammatory cytokine milieu (IL-2, IFN-γ upregulation; some anti-inflammatory effects on IL-6, TNF-α). These immune-activating effects are the basis for TA1's approved hepatitis indications and its use as a cancer immunoadjuvant.

For cancer applications, TA1's immune activation is systemically distributed. The therapeutic goal is immune activation at the tumor microenvironment (TME) — specifically, activation of CD4+ and CD8+ T cells that can infiltrate the tumor and attack cancer cells. Systemic immune activation via TA1 can enhance anti-tumor immunity, but the efficiency is limited because: (1) most activated immune cells do not specifically accumulate at the tumor; (2) the tumor microenvironment has strong immunosuppressive mechanisms that can overwhelm systemically activated T cells. Tumor-targeted delivery of TA1 could theoretically address both issues by concentrating the immune stimulus at the tumor site.

Arg-Gly-Asp (RGD) is the minimum integrin recognition sequence found in extracellular matrix proteins including fibronectin (the first identified RGD-containing protein; Ruoslahti & Pierschbacher 1987), vitronectin, osteopontin, and collagen. Integrins are cell surface heterodimeric receptors (αβ subunit pairs) that mediate cell adhesion to extracellular matrix. Integrin αvβ3 is a primary RGD-binding integrin that is expressed at low levels on normal quiescent endothelium but is substantially upregulated on tumor vasculature (angiogenic endothelium) and on many tumor cell surfaces including lung cancer, melanoma, glioblastoma, and others. This upregulation pattern makes αvβ3 a validated tumor-targeting handle — the same logic used by cilengitide (RGD-containing cyclic peptide) as an anti-angiogenic drug candidate.

RGDR adds a C-terminal Arg to the RGD core. This additional Arg is recognized by NRP-1 (neuropilin-1), a cell-surface receptor for VEGF and semaphorin families that is expressed on tumor vasculature and tumor cells. NRP-1 recognition by the C-terminal Arg/Lys residue of an RGD peptide (the R/KXXR/K NRP-1 recognition motif) has been shown to significantly enhance tumor penetration beyond what RGD-integrin binding alone achieves — this is the iRGD effect characterized by Sugahara et al. (Science 2010). The RGDR sequence therefore provides: αvβ3 binding (primary tumor surface attachment) + NRP-1 recognition (enhanced tumor penetration). The combination creates what the research papers describe as a 'tumor-penetrating peptide' that preferentially accumulates in tumor tissue.

Component

Target

Expression Pattern

Functional Role in Tα1-RGDR

RGD (Arg-Gly-Asp)

Integrin αvβ3

Low on quiescent endothelium; high on tumor vasculature and many tumor cell surfaces

Primary attachment to tumor vasculature; initiates tumor-directed accumulation of the fusion protein

Terminal Arg (RGDR)

NRP-1 (neuropilin-1)

Expressed on tumor vasculature and tumor cells; VEGF co-receptor

Enhances tumor penetration via NRP-1 pathway beyond integrin binding alone

GGGG linker

None (structural)

N/A

Conformational flexibility between TA1 and RGDR; prevents mutual interference of the two functional domains

Full TA1 (28 AA)

TLR9, STAT1/STAT3, T-cell receptors

Thymic and immune system expression; acts on T cells, DCs, NK cells

Immune activation (CD4+, CD8+ T cells; DC maturation; NK enhancement) concentrated at tumor-rich sites

Lao X, Liu M, Chen J, Zheng H. (2013). A Tumor-Penetrating Peptide Modification Enhances the Antitumor Activity of Thymosin Alpha 1. PLOS ONE. PMC3747120. Design: in vitro + in vivo mouse tumor models; Tα1 modified with iRGD (a cyclic RGD variant related to RGDR); H460 human lung cancer cell line and B16F10 mouse melanoma. In vitro: Tα1-iRGD maintained splenocyte proliferative activity (immune activation equivalent to TA1 alone) + showed greater and more specific binding to tumor cells vs TA1 alone. In vivo (mouse): Tα1-iRGD exhibited enhanced anti-proliferative activity against tumors compared to unmodified TA1. Conclusion: RGD modification enhances TA1 tumor penetration and anti-proliferative activity while preserving immune activation. Grade C: mouse models; H460 and B16F10 tumor lines; foundational proof-of-concept for the fusion approach.

Peng R, Xu C, Zheng H, Lao X. (2020). Modified Thymosin Alpha 1 Distributes and Inhibits the Growth of Lung Cancer in Vivo. ACS Omega. PMC7226852. Design: mouse tumor models specifically using Tα1-RGDR (the same compound sold by Limitless); H460 (human lung cancer) and LLC (Lewis Lung Carcinoma); in vivo tumor distribution and growth inhibition. Results: Tα1-RGDR showed 'remarkable antitumor effects'; tumor distribution/targeting was better than unmodified TA1; CD4+ and CD8+ T cell upregulation maintained; Tα1-RGDR specifically combines RGDR's αvβ3 and NRP-1 binding with TA1's immune activation. Conclusion: Tα1-RGDR is a 'promising antitumor drug.' Grade C: mouse tumor models; H460 and LLC; no human data.

Important pharmacological context from Peng 2020: integrin αvβ3 is overexpressed on H460 and LLC tumor surfaces, making these specific models appropriate for demonstrating the RGDR targeting mechanism. Whether this translates to human tumor αvβ3 expression patterns and Tα1-RGDR biodistribution in humans is uncharacterized.

Study

Design

Grade

Key Finding

Lao 2013 (PLOS ONE; PMC3747120)

Mouse; H460 + B16F10; in vitro + in vivo; Tα1-iRGD (related compound)

C (NHP/mouse)

Enhanced tumor penetration vs TA1 alone; anti-proliferative activity improved; immune activation preserved

Peng 2020 (ACS Omega; PMC7226852)

Mouse; H460 + LLC; in vivo; Tα1-RGDR (the Limitless compound specifically)

C (mouse)

Remarkable antitumor effects; better tumor targeting than TA1; CD4+/CD8+ T cells upregulated; 'promising antitumor drug'

Human clinical trial for Tα1-RGDR

Not conducted

None

No Phase 1/2/3 trial for this specific fusion compound

Full TA1 (Zadaxin) human evidence

Extensive; hepatitis B/C approvals; cancer adjuvant trials; COVID-19 programs

A-B

Separate compound; extensive human evidence for TA1 alone not directly applicable to the RGDR fusion

Tα1-RGDR contains full TA1 plus an additional RGDR tumor-targeting domain. The immunopharmacology is similar because the TA1 component is the same. But Tα1-RGDR is a larger, more complex fusion protein; it has different biodistribution (preferentially accumulating in tumor tissue); it interacts with integrin αvβ3 and NRP-1; and it has only mouse tumor model evidence rather than TA1's extensive clinical trial database. Substituting Tα1-RGDR for Zadaxin based on assumed equivalence ignores the meaningful differences in biodistribution and evidence base.

The RGDR tetrapeptide itself is a targeting sequence that binds integrin αvβ3. It does not independently produce immune activation. The therapeutic mechanism of Tα1-RGDR requires both components: RGDR provides tumor targeting; TA1 provides immune activation. Neither component alone produces the fusion's intended pharmacology.

H460 human lung cancer cells and LLC/B16F10 mouse tumor lines in mice are standard preclinical tumor models. These models confirm that Tα1-RGDR reaches tumor tissue better than TA1 alone and inhibits tumor growth. Whether human solid tumors express sufficient αvβ3 to allow comparable accumulation, whether the NRP-1 tumor penetration mechanism operates the same way in human tumor architecture, and whether the immune activation translates to clinical benefit requires human clinical trials that have not been conducted.

• General immune support without cancer: use unmodified TA1 (Zadaxin); extensive clinical evidence; approved in 35+ countries; the companion chapter (pbta1v4) covers this.
• Active cancer context: Tα1-RGDR is specifically designed for this; tumor-targeting mechanism is most relevant here; physician consultation mandatory; potential interactions with other immunotherapy require medical oversight.
• Evidence grade for Tα1-RGDR: C (mouse tumor models); zero human trials; the TA1 component inherits TA1's extensive human evidence, but the RGDR fusion construct itself has not been tested in humans.
• The structural fact: Tα1-RGDR is full 28-AA TA1 + GGGG + RGDR; it is NOT a small peptide fragment; it is a larger fusion protein with different biodistribution from unmodified TA1.

— End of Tα1-RGDR —

THE PEPTIDE BIBLE | Tα1-RGDR | For Research & Educational Purposes Only